Kiran Godse, Rashmi Sarkar, Venkataram Mysore, Manunath M Shenoy, Manas Chatterjee, Rajetha Damisetty, Swapnil Shah, Maya Vedamurthy, Sanjeev Aurangabadkar, Chakravarthi Srinivas, Anil Ganjoo, Sudip Das, Anant Patil
Melasma, a chronic pigmentary skin condition mainly affecting the face, remains a challenge despite the availability of several options for treatment. Many melasma patients are not satisfied with treatment outcomes. Tranexamic acid (TXA), an anti-fibrinolytic drug has shown promising results in patients with melasma. Evidence from several clinical studies has surfaced on efficacy and tolerability of TXA in these patients. It can be used as monotherapy or adjuvant with other therapies. Currently, there is no published consensus or guideline document for its use in the treatment of melasma...
2023: Indian Journal of Dermatology